Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. (NYSE: PEN) is described in its public communications as the world’s leading thrombectomy company, with a portfolio focused on computer assisted vacuum thrombectomy (CAVT™) and related devices for serious vascular and neurovascular conditions. The Penumbra news feed on this page aggregates company announcements, clinical trial updates and capital markets communications that shape how investors and clinicians follow the PEN stock story.
Recent news includes the announcement of a definitive Agreement and Plan of Merger with Boston Scientific Corporation, under which a Boston Scientific subsidiary will merge with and into Penumbra, leaving Penumbra as a wholly owned subsidiary if the transaction closes. The joint press release details the planned cash-and-stock consideration and notes that, upon completion, Penumbra’s securities are expected to be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934.
Beyond M&A developments, Penumbra’s news flow features earnings releases and preliminary financial updates furnished via Form 8-K, outlining revenue trends, margins and non-GAAP measures such as constant currency revenue and adjusted EBITDA. These items provide context on the company’s operating performance and financial outlook as it continues to develop and commercialize thrombectomy and embolization technologies.
Penumbra also issues news around clinical research milestones. Notable examples include results from the pivotal STORM-PE randomized controlled trial, which evaluated CAVT using Penumbra’s Lightning Flash™ plus anticoagulation versus anticoagulation alone in acute intermediate-high risk pulmonary embolism. Company press releases describe superior reductions in right heart strain, thrombus burden and improvements in functional outcomes for patients treated with CAVT plus anticoagulation, with comparable safety profiles between treatment arms.
Additional news items cover leadership changes and investor relations activities, such as the appointment of a new company president and scheduled presentations at healthcare and investor conferences, including the J.P. Morgan Healthcare Conference and other sector events. These updates highlight how Penumbra’s management communicates with the investment community and discusses its clinical and commercial strategy.
By following this PEN news page, readers can review a consolidated stream of Penumbra’s press releases, transaction announcements, clinical trial disclosures and financial updates, all of which are sourced from official company communications and SEC-related materials.
Penumbra, Inc. (NYSE: PEN), a leading thrombectomy company, has completed enrollment for its THUNDER clinical study evaluating the safety and efficacy of its latest computer assisted vacuum thrombectomy (CAVT™) technology for acute ischemic stroke patients. The study focuses on the Penumbra System™ with Thunderbolt™ Aspiration Tubing for removing blood clots in the brain.
The Thunderbolt technology uses an advanced CAVT software algorithm to generate modulated aspiration, aiming to reduce friction and facilitate faster, more complete clot removal. The THUNDER study (NCT05437055) is a multi-center, single-arm study involving patients with acute ischemic stroke due to intracranial large vessel occlusion (LVO) eligible for mechanical thrombectomy. The primary efficacy endpoint is the revascularization of the occluded target vessel immediately post-procedure.
The Get Out the Clot campaign has been launched by leading medical societies to improve patient care for venous thromboembolism (VTE). This collaborative initiative aims to identify gaps in care, standardize treatment, and expand access to innovative solutions for blood clot conditions. VTE affects up to 900,000 Americans annually, causing approximately 100,000 deaths and up to $10 billion in associated costs.
The campaign highlights the importance of standardized care paths and multidisciplinary approaches, such as VTE or PE response teams (PERTs), to improve diagnosis and treatment. It also emphasizes the need for awareness of newer treatments like computer-assisted vacuum thrombectomy and mechanical thrombectomy, which can quickly remove blood clots and improve patient outcomes.
The initiative is supported by organizations including the International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE: PEN), The PERT Consortium™, and the Society for Vascular Medicine (SVM).
Penumbra, Inc. (NYSE: PEN) has announced that it will release its financial results for the third quarter of 2024 after the market closes on Wednesday, October 30, 2024. The company will host a conference call to discuss these results at 4:30 PM Eastern Time on the same day.
Interested parties can access the conference call by dialing (888) 596-4144 with the conference ID: 5872954. Alternatively, a webcast of the call will be available on the 'Events and Presentations' section of Penumbra's website under the 'Investors' tab. The webcast will remain accessible on the company's website for at least two weeks following the call.
Penumbra, Inc. (NYSE: PEN) has received CE Mark approval in Europe for its latest computer assisted vacuum thrombectomy (CAVT) technologies – Lightning Flash™ 2.0 and Lightning Bolt™ 7. These advanced systems are designed to quickly restore blood flow by efficiently removing blood clots.
Lightning Flash 2.0, the most advanced thrombectomy system for venous and pulmonary thrombus in Europe, features dual clot detection algorithms and MaxID hypotube technology. Lightning Bolt 7, the most powerful arterial thrombectomy system, introduces modulated aspiration for rapid removal of large, fibrous blood clots in arteries.
These innovations aim to improve patient outcomes by enabling quicker procedures and more efficient clot removal while maintaining a high level of safety.
Penumbra Inc (NYSE: PEN) has announced its participation in the upcoming Baird Global Healthcare Conference. The company's management team is scheduled to present on Tuesday, September 10, 2024, at 9:05 AM ET / 6:05 AM PT. Investors and interested parties can access a webcast of the presentation through the 'Events and Presentations' section under the 'Investors' tab on Penumbra's official website.
The webcast will remain available on the company's website for at least two weeks following the event, providing an opportunity for those unable to attend the live presentation to review the content. This conference participation highlights Penumbra's commitment to engaging with the investment community and sharing insights about their healthcare innovations.
Penumbra, Inc. (NYSE: PEN) has announced its participation in the upcoming Wells Fargo Healthcare Conference. The company's management team is scheduled to present on Wednesday, September 4, 2024, at 2:15pm ET/11:15am PT. Interested parties can access a webcast of the presentation through the 'Events and Presentations' section under the 'Investors' tab on Penumbra's official website.
The webcast will remain available on the company's website for a minimum of two weeks following the event. This presentation provides an opportunity for investors and analysts to gain insights into Penumbra's current operations and future strategies within the healthcare sector.
Penumbra, Inc. (NYSE: PEN), a leading thrombectomy company, has announced a $200 million share repurchase authorization approved by its Board of Directors on August 5, 2024. The authorization, valid until July 31, 2025, allows Penumbra to repurchase its common stock through various methods. As part of this initiative, Penumbra has entered into a $100 million accelerated share repurchase agreement (ASR) with JPMorgan Chase Bank on August 12, 2024.
Under the ASR, Penumbra will make an initial payment of $100 million and receive approximately 474,000 shares of its common stock on August 13, 2024. The final number of shares repurchased will be determined based on the average daily volume-weighted average prices during the ASR term. The ASR is expected to be completed in the third quarter of 2024, funded by Penumbra's cash on hand.
Penumbra (NYSE: PEN) has announced its participation in the upcoming Canaccord Genuity Growth Conference. The company's management team is set to present on Tuesday, August 13, 2024, at 9:00 AM ET / 6:00 AM PT. This event provides an opportunity for investors and analysts to gain insights into Penumbra's growth strategies and market position.
Interested parties can access a webcast of the presentation through the 'Events and Presentations' section under the 'Investors' tab on Penumbra's official website. The webcast will remain available for at least two weeks following the event, allowing for extended viewing and analysis of the company's presentation.
Penumbra, Inc. (NYSE: PEN) reported Q2 2024 financial results with revenue of $299.4 million, up 14.5% year-over-year. U.S. thrombectomy revenue increased 24.9% to $153.7 million. The company reported a loss from operations of $81.0 million, including $110.3 million in one-time non-cash impairment charges. Excluding these charges, non-GAAP income from operations was $31.7 million.
Penumbra updated its 2024 revenue guidance to $1,180-$1,200 million, a $60 million reduction at the midpoint. This change reflects challenges in China, delays in European product launches, strategic changes in Immersive Healthcare, and adjusted U.S. thrombectomy growth expectations. The company maintains its outlook for non-GAAP gross margin and operating margin expansion.
Penumbra has scheduled its Q2 2024 earnings release and conference call for July 30, 2024, at 4:30 PM ET. The company will issue a press release with financial results after the market closes on that day. Investors can join the earnings call by dialing (888) 596-4144 with the conference ID 5872954 or access the webcast via Penumbra's website under the 'Investors' tab. The webcast will remain available for at least two weeks post-call.